JP2018506975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506975A5 JP2018506975A5 JP2017542093A JP2017542093A JP2018506975A5 JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5 JP 2017542093 A JP2017542093 A JP 2017542093A JP 2017542093 A JP2017542093 A JP 2017542093A JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chimeric protein
- domain
- cell
- caspase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1503133.9 | 2015-02-24 | ||
| GB201503133A GB201503133D0 (en) | 2015-02-24 | 2015-02-24 | Chimeric protein |
| PCT/GB2016/050451 WO2016135470A1 (en) | 2015-02-24 | 2016-02-23 | Chimeric protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Division JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506975A JP2018506975A (ja) | 2018-03-15 |
| JP2018506975A5 true JP2018506975A5 (enExample) | 2019-02-14 |
| JP6836508B2 JP6836508B2 (ja) | 2021-03-03 |
Family
ID=52822149
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542093A Active JP6836508B2 (ja) | 2015-02-24 | 2016-02-23 | キメラタンパク質 |
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10098911B2 (enExample) |
| EP (2) | EP3197453B9 (enExample) |
| JP (4) | JP6836508B2 (enExample) |
| KR (2) | KR102601849B1 (enExample) |
| CN (2) | CN116425882A (enExample) |
| AU (1) | AU2016225190B2 (enExample) |
| CA (1) | CA2973107C (enExample) |
| CL (1) | CL2017002134A1 (enExample) |
| DK (1) | DK3197453T3 (enExample) |
| ES (1) | ES2930623T3 (enExample) |
| GB (1) | GB201503133D0 (enExample) |
| HU (1) | HUE060267T2 (enExample) |
| IL (1) | IL252840B (enExample) |
| MX (1) | MX392658B (enExample) |
| PL (1) | PL3197453T3 (enExample) |
| PT (1) | PT3197453T (enExample) |
| RU (1) | RU2746755C2 (enExample) |
| SG (1) | SG11201705300VA (enExample) |
| WO (1) | WO2016135470A1 (enExample) |
| ZA (1) | ZA201704231B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| CA3007473A1 (en) * | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| WO2018068022A1 (en) * | 2016-10-06 | 2018-04-12 | Poseida Therapeutics, Inc. | Inducible caspases and methods for use |
| CA3045667A1 (en) | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| WO2018129563A1 (en) | 2017-01-09 | 2018-07-12 | Oisin Biotechnologies | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CN109593721B (zh) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技（上海）有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| EP3703689A1 (en) * | 2017-11-01 | 2020-09-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| JP7412006B2 (ja) * | 2018-03-14 | 2024-01-12 | メディジーン イミュノテラピーズ ゲーエムベーハー | 誘導性ｔ細胞レセプター及びその使用 |
| GB201805918D0 (en) | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| WO2019204666A1 (en) | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| GB201906126D0 (en) | 2019-05-01 | 2019-06-12 | Autolus Ltd | Chimeric protein |
| GB201910651D0 (en) | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| IT202000018064A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | Sviluppo di una nuova proteasi tobacco etch virus (tev) ingegnerizzata attivabile nel citosol o nel pathway secretorio |
| CN112575035B (zh) * | 2020-12-09 | 2022-11-29 | 贵州医科大学 | 一种诱导细胞凋亡的载体系统 |
| GB202019879D0 (en) | 2020-12-16 | 2021-01-27 | Ucl Business Ltd | Polypeptide |
| EP4267601A1 (en) | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| WO2024251225A1 (en) * | 2023-06-07 | 2024-12-12 | Nanjing Legend Biotech Co., Ltd. | Rapamycin resistant cells and methods of use thereof |
| WO2024256823A1 (en) | 2023-06-14 | 2024-12-19 | Autolus Limited | Treatment of trbc1-positive t cell malignancies |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| GB202405382D0 (en) | 2024-04-16 | 2024-05-29 | Ucl Business Ltd | Chimeric antigen receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| DE69637641D1 (de) * | 1995-06-07 | 2008-09-25 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| KR19990022651A (ko) * | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| AU3454799A (en) | 1998-03-30 | 1999-10-18 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US20040040047A1 (en) * | 1998-03-30 | 2004-02-26 | Spencer David M. | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6916917B1 (en) * | 1998-11-17 | 2005-07-12 | California Institute Of Technology | Chimeric pro-caspases and methods of using same |
| EP1509596A1 (en) | 2002-04-19 | 2005-03-02 | BioImage A/S | Translocation dependent complementation for drug screening |
| US20060263368A1 (en) * | 2005-01-10 | 2006-11-23 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| US20140189897A1 (en) * | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR101495651B1 (ko) * | 2012-09-03 | 2015-03-03 | 한국과학기술원 | 빛에 의해 이합체 형성을 유도하는 융합단백질 및 그의 용도 |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| EP3569253A1 (en) * | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3114217A4 (en) | 2014-03-07 | 2017-09-20 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| WO2016100236A2 (en) * | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
-
2015
- 2015-02-24 GB GB201503133A patent/GB201503133D0/en not_active Ceased
-
2016
- 2016-02-23 ES ES16707195T patent/ES2930623T3/es active Active
- 2016-02-23 EP EP16707195.0A patent/EP3197453B9/en active Active
- 2016-02-23 PT PT167071950T patent/PT3197453T/pt unknown
- 2016-02-23 EP EP22191585.3A patent/EP4147696A1/en active Pending
- 2016-02-23 WO PCT/GB2016/050451 patent/WO2016135470A1/en not_active Ceased
- 2016-02-23 AU AU2016225190A patent/AU2016225190B2/en active Active
- 2016-02-23 JP JP2017542093A patent/JP6836508B2/ja active Active
- 2016-02-23 RU RU2017132293A patent/RU2746755C2/ru active
- 2016-02-23 CA CA2973107A patent/CA2973107C/en active Active
- 2016-02-23 HU HUE16707195A patent/HUE060267T2/hu unknown
- 2016-02-23 US US15/526,097 patent/US10098911B2/en active Active
- 2016-02-23 CN CN202211656921.4A patent/CN116425882A/zh active Pending
- 2016-02-23 KR KR1020177025985A patent/KR102601849B1/ko active Active
- 2016-02-23 DK DK16707195.0T patent/DK3197453T3/da active
- 2016-02-23 PL PL16707195.0T patent/PL3197453T3/pl unknown
- 2016-02-23 SG SG11201705300VA patent/SG11201705300VA/en unknown
- 2016-02-23 MX MX2017007848A patent/MX392658B/es unknown
- 2016-02-23 KR KR1020237038544A patent/KR20230156817A/ko active Pending
- 2016-02-23 CN CN201680006920.1A patent/CN107207621B/zh active Active
-
2017
- 2017-06-12 IL IL252840A patent/IL252840B/en active IP Right Grant
- 2017-06-21 ZA ZA2017/04231A patent/ZA201704231B/en unknown
- 2017-08-21 CL CL2017002134A patent/CL2017002134A1/es unknown
-
2018
- 2018-08-27 US US16/113,098 patent/US10478457B2/en active Active
-
2019
- 2019-10-10 US US16/598,652 patent/US11103532B2/en active Active
-
2020
- 2020-03-06 JP JP2020038667A patent/JP2020078359A/ja not_active Withdrawn
-
2022
- 2022-06-08 JP JP2022092922A patent/JP2022111273A/ja active Pending
-
2024
- 2024-07-10 JP JP2024111258A patent/JP2024133176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017132293A (ru) | Химерный белок | |
| Willcox et al. | Butyrophilin-like 3 directly binds a human Vγ4+ T cell receptor using a modality distinct from clonally-restricted antigen | |
| Rice et al. | Recognition of the antigen-presenting molecule MR1 by a Vδ3+ γδ T cell receptor | |
| Li et al. | Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling | |
| Zeng et al. | γδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response | |
| EP3126380B1 (en) | Chimeric antigen receptor (car) signalling system | |
| EP3469362B1 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| JP2016538855A5 (enExample) | ||
| BR112020007576A2 (pt) | composições e métodos para degradação de proteína seletiva | |
| JP2018517410A5 (enExample) | ||
| JP2021533766A (ja) | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 | |
| JP2015518479A5 (enExample) | ||
| SG194398A1 (en) | Cross-species-specific psmaxcd3 bispecific single chain antibody | |
| Sharma et al. | Mucosal-associated invariant T cells develop an innate-like transcriptomic program in anti-mycobacterial responses | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2020530993A5 (enExample) | ||
| JP2019535292A5 (enExample) | ||
| Füchsl et al. | Adoptive cellular therapy for multiple myeloma using CAR-and TCR-transgenic T cells: response and resistance | |
| Harley et al. | Enhancement of hERG channel activity by scFv antibody fragments targeted to the PAS domain | |
| JP2021531834A (ja) | Ａｆｐ抗原を識別するｔ細胞受容体 | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| JP2024535814A (ja) | キメラ抗原受容体（ｃａｒ）シグナル伝達分子の組成物及びその使用 | |
| Lee et al. | Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein | |
| Füchsl et al. | Paving the way to solid tumors: Challenges and strategies for adoptively transferred transgenic T cells in the tumor microenvironment |